Novavax, Inc. (NVAX) Announces 4Q and Year-End 2016 Results; Shares Fall
- Author: Joanne Flowers Mar 02, 2017,
Mar 02, 2017, 19:43
Cantor Fitzgerald reaffirmed a hold rating and issued a $2.00 target price on shares of Novavax in a report on Friday, January 20th. This rating was issued on 12/16/16. BlackRock Group LTD now owns 161,349 shares of the biopharmaceutical company's stock valued at $335,000 after buying an additional 1,043 shares in the last quarter. For the stock, price target value has been calculated at $3.29 based on calls of 7 experts. State Street Corp now owns 19,971,040 shares of the biopharmaceutical company's stock valued at $25,163,000 after buying an additional 9,947,481 shares during the period. Moreover, Wedbush issued Downgrade rating for the stock on 16-Sep-16.
Novavax, Inc. (NASDAQ:NVAX) shares ended at $1.51 with 10.73 mln shares exchanging hands. Finally, Chardan Capital reiterated a "neutral" rating and issued a $1.50 target price on shares of Novavax in a research note on Friday, November 11th. Taking a look into the performance of NVAX stock, investor will come to know that the weekly performance for this stock is valued at 4.14%, resulting in a performance for the month at 13.53%.
Citigroup Downgrade its coverage for Novavax, Inc. The company now has an average rating of Hold and a consensus price target of $6.17.
Following U.S. election volatility some analysts have updated their recommended target prices on shares of Novavax, Inc. The analyst recommendations from a month ago are 14 Buy, 1 Overweight, 0 Sell, 1 Hold and 0 Underweight.
Some buy side analysts are also providing their Analysis on Novavax, Inc., where 1 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 7 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. A ROI of -53.60% for the company evaluates and compares the efficiency of the various numbers of investments relative to the cost of investments. Perceptive Advisors LLC bought a new stake in Novavax during the fourth quarter valued at approximately $423,000. (NASDAQ:NVAX) reported its Actual EPS of $-0.21/share. According to WSJ analysis, the Q4 2016 current estimates trends were for $0.20 as compared to the next year Q1 current trend of $0.20. For the current estimate trends of EPS, pool recommendation was $-0.52 and for one month was $-0.51. Thus the company showed an Earnings Surprise of 8.7 Percent.
Novavax, Inc. (NASDAQ:NVAX) holds the market capitalization of $522.23M along with 271.25M outstanding shares. Insiders own 0.30% of Novavax, Inc.'s (NVAX ) shares.
Novavax, Inc. on 02/27/2017 reported its EPS as $-0.21 with the analysts projecting the EPS of the stock as $-0.23. The company has a 1 Year high price target of $3.29. The stock's current distance from 20-Day Simple Moving Average (SMA20) is 6.8% where SMA50 and SMA200 are 8.98% and -60.96% respectively. Sectoral Asset Management Inc. now owns 912,305 shares of the biopharmaceutical company's stock worth $6,632,000 after buying an additional 499,805 shares during the last quarter. The Return on Equity (ROE) value stands at -189.1%. The stock has a 1-month performance of 63.36 percent and is 77.56 percent year-to-date as of the recent close.
Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Average Volume of the company is 7.03 Million and P/E (price to earnings) ratio is 0, while Forward P/E ratio is 0. The company projects a long term annual growth estimate of 0 percent.
On Feb. 27, 2017 Novavax, Inc., (NVAX) announced its financial results for the fourth quarter and twelve months ended December 31, 2016.